Arsenic trioxide

NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)

Retrieved on: 
Tuesday, January 23, 2024
Patient, Regenerative medicine, Fertility, Paratriathlon, AAV, Intercept Pharmaceuticals, Kite Pharma, University, Mitochondrion, Term sheet, LHON, Shearson, Acquisition, Safety, Vice, Intellectual property, FDA, Capsid, Letter, Arsenic trioxide, Paramount, Pharmaceutical industry

“The NAYA leadership team brings an agile entrepreneurial platform, broad development and commercialization experience, and access to public capital, which will unlock the potential of our promising AAV gene therapy platform for mitochondrial genetic diseases.

Key Points: 
  • “The NAYA leadership team brings an agile entrepreneurial platform, broad development and commercialization experience, and access to public capital, which will unlock the potential of our promising AAV gene therapy platform for mitochondrial genetic diseases.
  • The program has received over $6 million in grant funding to date and qualifies for Regenerative Medicine Advanced Therapy (RMAT) designation and multiple priority FDA review vouchers.
  • The combination of multiple orphan indications, multiple routes of administration, and multiple AAV serotypes applicable supports a broad gene therapy platform for mitochondrial orphan diseases.
  • The Florida Biotechnologies Transaction is contingent on the closing of the INVO Merger and sufficient financing to further develop the gene therapy programs from Florida Biotechnologies.

Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Tuesday, November 14, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Sale, Webcast, ID, Completeness, Incyte, Patient, Research, Chief commercial officer, APL, Bone marrow, RARA, Acute promyelocytic leukemia, Retirement, AML, Growth, Arsenic trioxide, Syro, Pharmaceutical industry, Management, Cryptocurrency, Pfizer, Syros

Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2023 and provided a corporate update.
  • In October 2023, Syros announced the retirement as Chief Executive Officer (CEO) of Nancy Simonian, M.D., effective December 1, 2023.
  • General and administrative expenses were $7.8 million for the third quarter of 2023, as compared to $8.1 million for the third quarter of 2022.
  • ET to discuss these third quarter 2023 financial results and provide a corporate update.

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Showcase Expansive Portfolio of Hematology/Oncology Data at the 65th American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
Tuesday, November 28, 2023
Acute promyelocytic leukemia, ATRA, NCI-designated Cancer Center, Research, Safety, RWJBarnabas Health, Toxicity, Progression-free survival, National Cancer Institute, Bone marrow, Ageing, ASH, Consortium, EFS, Clinical trial, Leukemia, Holism, Patient, PFS, Probability, APL, SWOG, Hodgkin lymphoma, Exposition, Multiple myeloma, CHL, Prognosis, Abstract, Diagnosis, Cancer, Death, Partnership, Arsenic trioxide, Society, Cooper University Hospital, Health, Lymphoma, Pharmaceutical industry, Medical device, MD

NEW BRUNSWICK, N.J., Nov. 28, 2023 /PRNewswire/ -- Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present an extensive array of hematology/oncology data from their clinical research program at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, being held in San Diego, California (and virtually) from December 9-12, 2023. A total of 36 abstracts have been accepted, comprising clinical data and analyses that advance the understanding, treatment, and prognosis of blood cancers such as lymphoma, leukemia, and myeloma. Rutgers Cancer Institute of New Jersey, in partnership with RWJBarnabas Health, is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.

Key Points: 
  • Rutgers Cancer Institute of New Jersey, in partnership with RWJBarnabas Health, is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.
  • "As the leading cancer program in the state, our commitment to advancing oncology care is unwavering.
  • The primary endpoint was progression-free survival (PFS), and secondary endpoints included overall survival (OS), event-free survival (EFS), and safety.
  • The full list of presentations at this year's ASH Annual Meeting and Exposition follows:

NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger

Retrieved on: 
Friday, November 10, 2023
Entrepreneurship, Vice, Pace University, Associate, Harvard Business School, Fertility, Lubin School of Business, Intercept Pharmaceuticals, Keynote, Science, Prentice Hall, Kite Pharma, Book, Yeshiva University, Paramount, Shearson, Management science, Polytechnic, Regenerative medicine, Daniel, FDA, Marketing, Nihon University, Hebrew University of Jerusalem, Bank, Therapy, MBA, Arsenic trioxide, Postgraduate education, Business, Management, Education

"I am delighted to join NAYA Biosciences upon the closing of its public merger," commented Dr. Peter Kash.

Key Points: 
  • "I am delighted to join NAYA Biosciences upon the closing of its public merger," commented Dr. Peter Kash.
  • "We welcome Peter to NAYA's board as we close our public merger with INVO and prepare to execute an ambitious growth strategy," added Dr. Daniel Teper, Chairman and CEO of NAYA Biosciences.
  • He is currently the cofounder and Vice Chairman of TargImmune Therapeutics (Switzerland) and cofounder and Managing Director of Camelot BioCapital.
  • Dr. Kash completed post graduate classes on Making Boards of Directors More Effective at Harvard Business School.

Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company

Retrieved on: 
Monday, October 2, 2023
Biotechnology, Health, Pharmaceutical, Cardiology, Oncology, Workforce, APL, University, Partnership, Arsenic trioxide, International business development, Pharming, Acute promyelocytic leukemia, Personalized medicine, Cancer, Business, CCO, RARA, Acute myeloid leukemia, MDS, AML, Azacitidine, Retirement, Novartis, Patient, CBO, Biology, Bone marrow, Growth, Venetoclax, Pfizer, Clinical pharmacy, Management, Pharmaceutical industry, Capmatinib, Pasireotide, Syros

Also today, Syros announced the retirement as Chief Executive Officer (CEO) of Nancy Simonian, M.D., and the appointment of Conley Chee, Syros’ Chief Commercial Officer (CCO) and Chief Business Officer (CBO), as CEO, effective December 2, 2023.

Key Points: 
  • Also today, Syros announced the retirement as Chief Executive Officer (CEO) of Nancy Simonian, M.D., and the appointment of Conley Chee, Syros’ Chief Commercial Officer (CCO) and Chief Business Officer (CBO), as CEO, effective December 2, 2023.
  • Dr. Simonian will remain a member of the Syros Board of Directors following the transition.
  • This includes streamlining our team and, due to capital constraints, stopping further investment in SY-2101 for the foreseeable future.
  • As we look toward near-term data catalysts from SELECT-MDS-1 and SELECT-AML-1, we are planning for our next phase of growth.

Syros Announces Clinical Updates and 2023 Strategic Priorities

Retrieved on: 
Monday, January 9, 2023
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Disease, MDS, Phenotype, Toxicity, RARA, Roche, AML, Arsenic trioxide, Safety, Azacitidine, AUC, Pancreatic cancer, SELECT, Venetoclax, APL, BRAF, ASH, Partnership, Lymphatic system, Patient, Society, Syros, Pharmaceutical industry, Cmax

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in advancing new standards of care for the frontline treatment of hematologic malignancies, today provided an update on its clinical development programs and outlined its strategic priorities for 2023.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a leader in advancing new standards of care for the frontline treatment of hematologic malignancies, today provided an update on its clinical development programs and outlined its strategic priorities for 2023.
  • Syros currently has over 75 clinical sites open for recruitment in 12 countries.
  • Syros expects to complete patient enrollment in SELECT-MDS-1 in the fourth quarter of 2023, with data to follow in the third quarter of 2024.
  • Syros is developing SY-2101, a novel oral form of arsenic trioxide (ATO) for the treatment of newly diagnosed APL patients.

Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS

Retrieved on: 
Monday, December 12, 2022
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Genome, Security (finance), ORR, Observation, Freedom, Azacitidine, Venetoclax, Institut Gustave Roussy, Patient, CR, Toxicity, Tamibarotene, Annual report, Compte rendu, Biology, Aplastic anemia, Arsenic trioxide, Myelodysplastic syndrome, Government, COVID-19, AML, Clinical trial, Safety, CDK7, Workforce, MDS, Acute myeloid leukemia, Gene, AES, RARA, Acute promyelocytic leukemia, Pharmaceutical industry, Syros

These findings support Syros ongoing evaluation of tamibarotene for the treatment of AML and myelodysplastic syndrome (MDS) patients with RARA overexpression.

Key Points: 
  • These findings support Syros ongoing evaluation of tamibarotene for the treatment of AML and myelodysplastic syndrome (MDS) patients with RARA overexpression.
  • The biomarker test successfully identified AML patients positive for RARA overexpression who were enriched for response to tamibarotene and azacitidine relative to those patients who were negative for RARA overexpression.
  • This observation further demonstrates that the activity of tamibarotene is dependent on the biology of RARA overexpression.
  • Based on RARA expression levels, each patient was classified as positive for RARA overexpression (22 patients) or negative for RARA overexpression (29 patients).

Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial

Retrieved on: 
Saturday, December 10, 2022
Health, FDA, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Genome, Pneumonia, University of Colorado School of Medicine, Society, Toxicity, Aplastic anemia, Disease, Government, Patient, COVID-19, AML, ELN, Gene, Anxiety, Phenotype, Associate, Diagnosis, Rash, Șaeș, DiNardo, Arsenic trioxide, Clinical trial, University, Toxic leukoencephalopathy, Acute promyelocytic leukemia, Security (finance), Webcast, The New England Journal of Medicine, Leukemia, Cough, CRi, European, Workforce, ASH, RARA, IWG, Freedom, Salvage therapy, CR, Elevated railway, Annual report, Compte rendu, Blood, Safety, CDK7, Acute myeloid leukemia, AES, Febrile neutropenia, Pharmaceutical industry, Medical device, Azacitidine, Syros, Venetoclax

As of October 13, 2022, eight newly diagnosed, unfit, RARA-positive patients had been enrolled in the trial, including six who were evaluable for response.

Key Points: 
  • As of October 13, 2022, eight newly diagnosed, unfit, RARA-positive patients had been enrolled in the trial, including six who were evaluable for response.
  • - Tamibarotene in combination with venetoclax and azacitidine administered at approved doses showed no evidence of increased toxicity relative to the doublet combination of venetoclax and azacitidine.
  • This includes rates of myelosuppression, which were comparable to reports with venetoclax and azacitidine in this population.
  • The randomized portion is expected to initiate in Q1 2023, with data expected in 2023 or 2024.

Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10

Retrieved on: 
Monday, December 5, 2022
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, Genome, Syros, Webcast, University of Colorado School of Medicine, Leukemia, Society, Patient, Arsenic trioxide, Associate, AML, Clinical trial, University, Safety, CDK7, Acute myeloid leukemia, Gene, ASH, RARA, Acute promyelocytic leukemia, Pharmaceutical industry

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a virtual event to discuss initial data from the safety lead-in portion of the ongoing Phase 2 SELECT-AML-1 clinical trial and to review the unmet need in newly diagnosed, unfit acute myeloid leukemia (AML).

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a virtual event to discuss initial data from the safety lead-in portion of the ongoing Phase 2 SELECT-AML-1 clinical trial and to review the unmet need in newly diagnosed, unfit acute myeloid leukemia (AML).
  • The event will be held on Saturday, December 10, 2022 beginning at 12:00 p.m.
  • In addition, a live webcast of the presentation will be available on the Investors & Media section of the Syros website at www.syros.com .
  • Initial data from the SELECT-AML-1 trial will also be presented on Saturday, December 10, 2022 in a poster session at the 64th American Society of Hematology (ASH) Annual Meeting.

Syros to Participate at Piper Sandler 34th Annual Healthcare Conference

Retrieved on: 
Tuesday, November 22, 2022
Health, Biometrics, Genetics, Other Health, Pharmaceutical, Biotechnology, Arsenic trioxide, Syros, RARA, Lotte New York Palace Hotel, Acute myeloid leukemia, Conference, Madison Avenue, Piper Sandler Companies, CDK7, Gene, Acute promyelocytic leukemia, Webcast, Patient, Genome, Pharmaceutical industry

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference.
  • An archived replay of the webcast will be available for approximately 30 days following the presentation.
  • Syros is redefining the power of small molecules to control the expression of genes.
  • Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.